YILI CHUANNING BIOTECHNOLOGY CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.34 CNY | +2.14% |
|
-3.61% | +58.81% |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +58.81% | 4.09B | - | ||
| +51.63% | 796B | C+ | ||
| +41.51% | 628B | B | ||
| -5.10% | 358B | C+ | ||
| +19.90% | 331B | B- | ||
| +9.95% | 301B | C+ | ||
| +17.66% | 244B | B+ | ||
| +3.39% | 228B | A+ | ||
| +10.75% | 214B | B- | ||
| +6.99% | 165B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 301301 Stock
- Ratings Yili Chuanning Biotechnology Co.,Ltd.
